



Patent Ductus Arteriosus in Preterm Infants

William E. Benitz, MD, FAAP, COMMITTEE ON FETUS AND NEWBORN

Despite a large body of basic science and clinical research and clinical experience with thousands of infants over nearly 6 decades,¹ there is still uncertainty and controversy about the significance, evaluation, and management of patent ductus arteriosus in preterm infants, resulting in substantial heterogeneity in clinical practice. The purpose of this clinical report is to summarize the evidence available to guide evaluation and treatment of preterm infants with prolonged ductal patency in the first few weeks after birth.

abstract

CLINICAL EPIDEMIOLOGY AND NATURAL HISTORY OF PATENT DUCTUS ARTERIOSUS

In term infants, the ductus arteriosus normally constricts after birth and becomes functionally closed by 72 hours of age.² In preterm infants, however, closure is delayed, remaining open at 4 days of age in approximately 10% of infants born at 30 through 37 weeks' gestation, 80% of those born at 25 through 28 weeks' gestation, and 90% of those born at 24 weeks' gestation.³ By day 7 after birth, those rates decline to approximately 2%, 65%, and 87%, respectively. The ductus is likely to close without treatment in infants born at >28 weeks' gestation (73%),⁴ in those with birth weight >1000 g (94%),⁵ and in infants born at 26 through 29 weeks' gestation who do not have respiratory distress syndrome (93%).⁶ Rates of later spontaneous ductal closure among smaller, less mature infants with respiratory distress syndrome are not known because of widespread use of treatments to achieve closure of the patent ductus arteriosus (PDA) in such infants. Data from placebo arms of controlled trials demonstrate that spontaneous ductal closure in these infants is frequent, however. In the Trial of Indomethacin Prophylaxis in Preterms, for example, which included infants with birth weight from 500 to 999 g, 50% of placebo recipients never developed clinical signs of a PDA.⁷ In a trial of early versus late indomethacin treatment of infants born at 26 through 31 weeks' gestation in whom PDA was confirmed by echocardiography on day 3, the ductus closed spontaneously by 9 days of age in 78% of those randomized to late intervention.⁸

FREE

This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication.

Clinical reports from the American Academy of Pediatrics benefit from expertise and resources of liaisons and internal (AAP) and external reviewers. However, clinical reports from the American Academy of Pediatrics may not reflect the views of the liaisons or the organizations or government agencies that they represent.

The guidance in this report does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

All clinical reports from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

DOI: 10.1542/peds.2015-3730

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2016 by the American Academy of Pediatrics

To cite: Benitz WE and COMMITTEE ON FETUS AND NEWBORN. Patent Ductus Arteriosus in Preterm Infants. *Pediatrics*. 2016;137(1):e20153730

While the ductus remains open, blood typically flows left-to-right from the aorta into the pulmonary arteries. As pulmonary vascular resistance declines over the first several days after birth, the proportion of aortic blood flow that is diverted into the pulmonary circulation correspondingly increases. This “ductal steal” results in excessive blood flow through the lungs, predisposing to development of pulmonary congestion, pulmonary edema, and worsening respiratory failure. Diversion of blood flow from the systemic circulation may exceed capabilities for compensatory increases in total cardiac output, resulting in compromised perfusion of vital organs, including bowel, kidney, and brain. Prolonged patency is associated with numerous adverse outcomes, including prolongation of assisted ventilation and higher rates of death, bronchopulmonary dysplasia (BPD), pulmonary hemorrhage, necrotizing enterocolitis, impaired renal function, intraventricular hemorrhage (IVH), periventricular leukomalacia, and cerebral palsy.⁹ The extent to which these adverse outcomes are attributable to the hemodynamic consequences of ductal patency, if at all, has not been established. The strength of these associations led to the hypothesis that intervention to close the ductus might prevent or reduce the severity of these common complications of prematurity. The expectation that this hypothesis would be confirmed, in turn, resulted in widespread adoption of interventions designed to achieve early closure of the ductus in preterm infants.

ASSESSMENT OF HEMODYNAMIC SIGNIFICANCE

The hemodynamic effects of a large left-to-right shunt associated with a PDA may be evident by physical examination, echocardiography, or measurement of serum biomarkers.

In addition to the presence of a classic coarse systolic murmur at the left sternal border, affected infants may have an increased precordial impulse, prominent or bounding arterial pulses, palpable pulses in the palms of the hands, and either low systolic and diastolic blood pressure or low diastolic blood pressure with a widened pulse pressure. Nevertheless, these findings are nonspecific, do not correlate well with echocardiographic findings,¹⁰ and have not been shown to reliably predict responses to treatment or sequelae. In many instances, the presence of a large ductal shunt is suspected only on the basis of respiratory findings, such as radiographic signs of pulmonary congestion, increasing requirements for supplemental oxygen, or inability to reduce mechanical ventilator support. The presence of a PDA is most definitively demonstrated by color Doppler echocardiography, which permits confirmation of ductal patency, measurement of ductal dimensions, and assessment of the direction and velocity of ductal blood flow throughout the cardiac cycle. Substantial ductal shunting may be associated with an increased ratio of left atrial to aortic root dimensions $\geq 1.5:1$, ductal diameter ≥ 1.5 mm, left ventricular volume and pressure loading, and reversal of diastolic flow in the descending aorta or in cerebral or renal arteries.^{11,12} Serum concentrations of natriuretic peptides (BNP or N-terminal of the prohormone BNP) are elevated in preterm infants with PDA,^{13,14} correlate with echocardiographic measures of shunt volume,¹⁴⁻¹⁶ and decrease after ductal closure.^{14,16} Concentrations of troponin T at 48 hours of age are higher in infants with PDA.¹⁷

The term “hemodynamically significant” is frequently used to differentiate consequential from inconsequential PDA. Neither the best tool nor the optimal thresholds

for identification of infants at greatest risk for adverse sequelae have been delineated. The predictive values of individual echocardiographic measurements are low, but some progress has been made toward correlation of composite scores with risks of adverse long-term outcome, including BPD¹⁸ or neurodevelopmental outcome at 2 years of age.¹² Exploratory studies suggest that elevated concentrations of either N-terminal of the prohormone BNP or troponin T at 48 hours of age may help predict death or severe IVH¹⁹ as well as neurodevelopment at 2 years of age.¹² The presence of a “hemodynamically significant” PDA has been correlated with lower regional cerebral oxygen saturation and higher fractional oxygen extraction²⁰ and with reduced celiac artery flow,²¹ supporting the hypothesis that prolonged ductal patency may have a causal role in substantial and enduring adverse outcomes. Development of an integrated definition of “hemodynamic significance” of PDA will be essential to risk stratification for clinical trials of PDA treatment, but this goal remains elusive.

EVIDENCE FOR BENEFITS OF TREATMENT

Since the early reports of feasibility of surgical closure²² and efficacy of nonsteroidal antiinflammatory drugs for medical treatment^{23,24} of PDA, results have been reported for 50 randomized controlled trials enrolling 4878 preterm infants.^{9,25} Although medical and surgical treatments are efficacious in closing the PDA in a large proportion of infants, neither individual clinical trials nor meta-analyses have demonstrated that closing the ductus results in improved long-term outcomes. Odds ratios for the most important outcomes (BPD, necrotizing enterocolitis, neurosensory impairment, death,

the combined outcomes of death or BPD and death or neurosensory impairment) indicate that early, routine treatment has no effect, with narrow confidence intervals, so it is unlikely that substantial differences have gone undetected.⁹ When given as prophylaxis for IVH beginning within 12 hours of birth, treatment with indomethacin reduces rates of IVH, IVH greater than grade II, and early, severe pulmonary hemorrhage but does not improve long-term neurodevelopmental or respiratory outcomes.^{7,26–28} The early neuroprotective effects of indomethacin may not depend on effects on ductal patency and are not replicated with similar use of ibuprofen.²⁹ In all published trials of prophylaxis or treatment, interventions were initiated within 2 weeks after birth for almost all subjects in the treatment arms, and later backup treatment to achieve ductal closure was common among control subjects.^{30,31} The available evidence is therefore insufficient to permit assessment of potential benefits of treatments initiated after 2 weeks of age. The cumulative evidence supports the conclusion that early (in the first 2 weeks after birth), routine (as prophylaxis or for infants with echocardiographic confirmation of ductal patency with or without clinical signs) treatment to close the ductus arteriosus does not improve long-term outcomes for preterm infants. There is insufficient evidence to determine whether there are preterm infants who might benefit from early treatment or that later treatment has no potential benefit. These data also cannot be extrapolated to novel treatments (such as acetaminophen, recently reported to promote ductal closure^{32,33}) because the balance between beneficial and adverse effects of new treatments may differ substantially from that for previously studied treatments.

Although surgical ligation is effective for achievement of rapid, complete ductal closure, it is often followed by severe hemodynamic and respiratory collapse, requiring marked escalation in supportive intensive care.³⁴ The risk of this complication appears to decline substantially over the first 6 weeks after birth.³⁵ Long-term complications of surgical ligation include paresis of the left vocal cord^{36,37} or diaphragm,³⁸ chylothorax,^{38–40} and scoliosis,^{41,42} and infants who undergo surgical ligation are more likely to develop BPD,^{43–45} retinopathy of prematurity,⁴⁵ and neurodevelopmental impairment.^{45,46} Treatment with cyclooxygenase inhibitors may lead to impaired renal function,⁴⁷ intestinal perforation,^{48,49} and altered cerebrovascular regulation.⁵⁰ In contrast to prophylactic use, treatment of confirmed PDA with indomethacin is associated with an increased risk of IVH.⁹ Treatment to close a patent ductus may therefore not be entirely benign.

Clinical experience with less aggressive strategies for PDA management suggests that a more permissive approach does not result in worse outcomes. Strategies avoiding use of indomethacin or ibuprofen yield outcomes comparable to contemporaneous external benchmarks.^{51,52} Less frequent use of surgical ligation in infants with PDA after failure of indomethacin prophylaxis was associated with a lower rate of necrotizing enterocolitis and no increase in rates of other adverse outcomes.⁵³ Reduced use of indomethacin and ligation at 1 center was associated with an increased rate of the combined outcome of death or chronic lung disease but no increase in rates of individual morbidities or mortality.⁵⁴ These experiences indicate that longer periods of exposure to left-to-right ductal shunting may not result in

significantly compromised outcomes, supporting equipoise regarding enrollment of preterm infants into randomized trials designed to assess treatment strategies for preterm infants with PDA.

CLINICAL TRIAL OPPORTUNITIES

As previously noted, evidence-based abandonment of early routine treatment to close the PDA does not preclude other options for management of infants with this condition. First, deciding not to intervene routinely to achieve earlier closure of the ductus should not imply that consequences of ductal patency can be completely ignored.⁵⁵ Although many strategies for management of the consequences of PDA have been proposed, none have been subjected to systematic evaluation in clinical trials, which are urgently needed to guide management of these infants. Studies of interventions designed to limit excessive pulmonary blood flow (red cell transfusion, increased positive airway pressure, correction of alkalosis, avoidance of pulmonary vasodilators such as oxygen or nitric oxide), to increase systemic cardiac output (dopamine, captopril, avoidance of hypovolemia), to ameliorate pulmonary edema (fluid restriction, diuretics, correction of hypoproteinemia), or to minimize confounding insults (nephrotoxic drugs, systemic infection/inflammation, hypoxemia, hypocarbia) may be appropriate. Second, early identification of a subset of infants with PDA who are at particular risk on the basis of echocardiographic, serum biomarker, or hemodynamic monitoring (such as measurement of cerebral oxygen saturation or fractional oxygen extraction) may allow more selective treatment in the first 2 weeks after birth. Because few extremely preterm infants (those born at ≤ 25 weeks, for example) were included in extant

trials, they may constitute a high-risk group with potential benefit from early, universal treatment. Similarly, criteria for intervention after the second postnatal week need to be developed. Although early experience suggested that infants more than 10 to 14 days of age are unlikely to respond to medical treatment with ductal closure,^{56,57} other analyses have suggested that postmenstrual, not postnatal, age is the critical determinant, with efficacy declining sharply after approximately 33 to 34 weeks' postmenstrual age.^{58,59} Therefore, selective treatment of infants born at or before 28 weeks' gestation, who are at highest risk of PDA, may remain an option well beyond 2 weeks' postnatal age. Deferral of treatment may allow avoidance of treatment of those in whom spontaneous closure occurs without seriously compromising the potential efficacy of medical treatment. Delaying ligation may have similar advantages, avoiding surgery in many infants in whom the ductus closes without treatment and reducing the risk of postoperative hemodynamic compromise in those who do require surgery, particularly if surgery can be deferred until after 30 days of age.

Additional research is needed to address 2 broad questions related to prolonged ductal patency in preterm infants. First, the relationship between measures of hemodynamic significance and increased risks for both prolonged patency and adverse clinical outcomes, such as chronic lung disease or neurodevelopmental impairment, needs to be established. Preliminary work using echocardiographic scores and serum biomarkers, described previously, provides a promising foundation for these studies. That information is extremely important for selection of appropriate subjects for enrollment in intervention trials. Second, well-designed and meticulously executed intervention trials, for which the

end points are clinically important long-term outcomes and not simply rates of ductal closure or measures of short-term physiologic changes, are essential. In these trials, both treatment arms must be explicitly defined so that the superior strategy can be replicated in clinical practice and evaluated against alternatives in future trials. If it is not feasible to forgo use of rescue treatment in the control (placebo or late-treatment) arm, strict criteria for both a required time interval and diagnostic thresholds for such treatment are desirable. Without clear demonstration that adverse outcomes can be averted by medical or surgical closure of the ductus, the hypothesis that ductal patency is causal with respect to those outcomes remains unproven.

CONCLUSIONS

A large body of evidence now exists demonstrating that early, routine treatment to induce closure of the ductus in preterm infants, either medically or surgically, in the first 2 weeks after birth does not improve long-term outcomes (level of evidence: 1A⁶⁰). The role of more selective use of medical methods for induction of ductal closure, either for defined high-risk infants in the first 2 postnatal weeks, or more generally, for older infants in whom the ductus remains patent, remains uncertain and requires further study. Prophylactic use of indomethacin may be appropriate in settings where rates of IVH are high or if early, severe pulmonary hemorrhage is common, but may not be justified by expected effects on PDA or by an expectation of better long-term outcomes. There is a lack of evidence to guide management of PDA, necessitating equipoise regarding treatment options and support for parents to permit enrollment of their infants in trials that can expand the available body of evidence.

AAP COMMITTEE ON FETUS AND NEWBORN, 2014–2015

Kristi L. Watterberg, MD, FAAP, Chairperson
Susan Aucott, MD, FAAP
William E. Benitz, MD, FAAP
James J. Cummings, MD, FAAP
Eric C. Eichenwald, MD, FAAP
Jay Goldsmith, MD, FAAP
Brenda B. Poindexter, MD, FAAP
Karen Puopolo, MD, FAAP
Dan L. Stewart, MD, FAAP
Kasper S. Wang, MD, FAAP

LIAISONS

Captain Wanda D. Barfield, MD, MPH, FAAP –
Centers for Disease Control and Prevention
James Goldberg, MD – *American College of
Obstetricians and Gynecologists*
Thierry Lacaze, MD – *Canadian Pediatric Society*
Erin L. Keels, APRN, MS, NNP-BC – *National
Association of Neonatal Nurses*
Tonse N.K. Raju, MD, DCH, FAAP – *National
Institutes of Health*

STAFF

Jim Couto, MA

ABBREVIATIONS

BPD: bronchopulmonary
dysplasia
IVH: intraventricular hemorrhage
PDA: patent ductus arteriosus

REFERENCES

1. Burnard ED. A murmur from the ductus arteriosus in the newborn baby. *BMJ*. 1958;1(5074):806–810
2. Gentile R, Stevenson G, Dooley T, Franklin D, Kawabori I, Pearlman A. Pulsed Doppler echocardiographic determination of time of ductal closure in normal newborn infants. *J Pediatr*. 1981;98(3):443–448
3. Clyman RI, Couto J, Murphy GM. Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all? *Semin Perinatol*. 2012;36(2):123–129
4. Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. *Pediatrics*. 2006;117(4):1113–1121

5. Nemerofsky SL, Parravicini E, Bateman D, Kleinman C, Polin RA, Lorenz JM. The ductus arteriosus rarely requires treatment in infants > 1000 grams. *Am J Perinatol.* 2008;25(10):661–666
6. Reller MD, Rice MJ, McDonald RW. Review of studies evaluating ductal patency in the premature infant. *J Pediatr.* 1993;122(6):S59–S62
7. Schmidt B, Davis P, Moddemann D, et al; Trial of Indomethacin Prophylaxis in Preterms Investigators. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. *N Engl J Med.* 2001;344(26):1966–1972
8. Van Overmeire B, Van de Broek H, Van Laer P, Weyler J, Vanhaesebrouck P. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. *J Pediatr.* 2001;138(2):205–211
9. Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? *J Perinatol.* 2010;30(4):241–252
10. Skelton R, Evans N, Smythe J. A blinded comparison of clinical and echocardiographic evaluation of the preterm infant for patent ductus arteriosus. *J Paediatr Child Health.* 1994;30(5):406–411
11. McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. *Arch Dis Child Fetal Neonatal Ed.* 2007;92(6):F424–F427
12. El-Khuffash AF, Slevin M, McNamara PJ, Molloy EJ. Troponin T, N-terminal pro natriuretic peptide and a patent ductus arteriosus scoring system predict death before discharge or neurodevelopmental outcome at 2 years in preterm infants. *Arch Dis Child Fetal Neonatal Ed.* 2011;96(2):F133–F137
13. Choi BM, Lee KH, Eun BL, et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. *Pediatrics.* 2005;115(3). Available at: www.pediatrics.org/cgi/content/full/115/3/e255
14. Flynn PA, da Graca RL, Auld PA, Nesin M, Kleinman CS. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. *J Pediatr.* 2005;147(1):38–42
15. El-Khuffash AF, Amoroso M, Culliton M, Molloy EJ. N-terminal pro-B-type natriuretic peptide as a marker of ductal haemodynamic significance in preterm infants: a prospective observational study. *Arch Dis Child Fetal Neonatal Ed.* 2007;92(5):F421–F422
16. Sanjeev S, Pettersen M, Lua J, Thomas R, Shankaran S, L'Ecuyer T. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. *J Perinatol.* 2005;25(11):709–713
17. El-Khuffash AF, Molloy EJ. Influence of a patent ductus arteriosus on cardiac troponin T levels in preterm infants. *J Pediatr.* 2008;153(3):350–353
18. Sehgal A, Paul E, Menahem S. Functional echocardiography in staging for ductal disease severity: role in predicting outcomes. *Eur J Pediatr.* 2013;172(2):179–184
19. El-Khuffash A, Barry D, Walsh K, Davis PG, Molloy EJ. Biochemical markers may identify preterm infants with a patent ductus arteriosus at high risk of death or severe intraventricular haemorrhage. *Arch Dis Child Fetal Neonatal Ed.* 2008;93(6):F407–F412
20. Lemmers PM, Toet MC, van Bel F. Impact of patent ductus arteriosus and subsequent therapy with indomethacin on cerebral oxygenation in preterm infants. *Pediatrics.* 2008;121(1):142–147
21. El-Khuffash A, Higgins M, Walsh K, Molloy EJ. Quantitative assessment of the degree of ductal steal using celiac artery blood flow to left ventricular output ratio in preterm infants. *Neonatology.* 2008;93(3):206–212
22. Gupta JM, Van Vliet PK, Fisk GC, Wright JS. Ductus ligation in respiratory distress syndrome. *J Thorac Cardiovasc Surg.* 1972;63(4):642–647
23. Friedman WF, Hirschklau MJ, Printz MP, Pitlick PT, Kirkpatrick SE. Pharmacologic closure of patent ductus arteriosus in the premature infant. *N Engl J Med.* 1976;295(10):526–529
24. Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. *N Engl J Med.* 1976;295(10):530–533
25. Kluckow M, Jeffery M, Gill A, Evans N. A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. *Arch Dis Child Fetal Neonatal Ed.* 2014;99(2):F99–F104
26. Ment LR, Vohr B, Allan W, et al. Outcome of children in the indomethacin intraventricular hemorrhage prevention trial. *Pediatrics.* 2000;105(3 pt 1):485–491
27. Rheinlaender C, Helfenstein D, Pees C, et al. Neurodevelopmental outcome after COX inhibitor treatment for patent ductus arteriosus. *Early Hum Dev.* 2010;86(2):87–92
28. Alfaleh K, Smyth JA, Roberts RS, Solimano A, Asztalos EV, Schmidt B; Trial of Indomethacin Prophylaxis in Preterms Investigators. Prevention and 18-month outcomes of serious pulmonary hemorrhage in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in preterms. *Pediatrics.* 2008;121(2). Available at: www.pediatrics.org/cgi/content/full/121/2/e233
29. Ohlsson A, Shah SS. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. *Cochrane Database Syst Rev.* 2011;(7):CD004213
30. Clyman RI, Chorne N. Patent ductus arteriosus: evidence for and against treatment. *J Pediatr.* 2007;150(3):216–219
31. Clyman RI. Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies. *J Pediatr.* 1996;128(5 pt 1):601–607
32. Hammerman C, Bin-Nun A, Markovitch E, Schimmel MS, Kaplan M, Fink D. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. *Pediatrics.* 2011;128(6). Available at: www.pediatrics.org/cgi/content/full/128/6/e1618

33. Oncel MY, Yurttutan S, Erdeve O, et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. *J Pediatr*. 2014;164(3):510–4.e1
34. Teixeira LS, Shivananda SP, Stephens D, Van Arsdell G, McNamara PJ. Postoperative cardiorespiratory instability following ligation of the preterm ductus arteriosus is related to early need for intervention. *J Perinatol*. 2008;28(12):803–810
35. Teixeira LS, McNamara PJ. Enhanced intensive care for the neonatal ductus arteriosus. *Acta Paediatr*. 2006;95(4):394–403
36. Clement WA, El-Hakim H, Phillipos EZ, Coté JJ. Unilateral vocal cord paralysis following patent ductus arteriosus ligation in extremely low-birth-weight infants. *Arch Otolaryngol Head Neck Surg*. 2008;134(1):28–33
37. Smith ME, King JD, Elsharif A, Muntz HR, Park AH, Kouretas PC. Should all newborns who undergo patent ductus arteriosus ligation be examined for vocal fold mobility? *Laryngoscope*. 2009;119(8):1606–1609
38. Mandhan P, Brown S, Kukkady A, Samarakkody U. Surgical closure of patent ductus arteriosus in preterm low birth weight infants. *Congenit Heart Dis*. 2009;4(1):34–37
39. Gould DS, Montenegro LM, Gaynor JW, et al. A comparison of on-site and off-site patent ductus arteriosus ligation in premature infants. *Pediatrics*. 2003;112(6 pt 1):1298–1301
40. Lippmann M, Nelson RJ, Emmanouilides GC, Diskin J, Thibeault DW. Ligation of patent ductus arteriosus in premature infants. *Br J Anaesth*. 1976;48(4):365–369
41. Roclawski M, Sabiniewicz R, Potaz P, et al. Scoliosis in patients with aortic coarctation and patent ductus arteriosus: does standard posterolateral thoracotomy play a role in the development of the lateral curve of the spine? *Pediatr Cardiol*. 2009;30(7):941–945
42. Shelton JE, Julian R, Walburgh E, Schneider E. Functional scoliosis as a long-term complication of surgical ligation for patent ductus arteriosus in premature infants. *J Pediatr Surg*. 1986;21(10):855–857
43. Chorne N, Leonard C, Piecuch R, Clyman RI. Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. *Pediatrics*. 2007;119(6):1165–1174
44. Clyman R, Cassady G, Kirklín JK, Collins M, Philips JB III. The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial. *J Pediatr*. 2009;154(6):873–876
45. Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanaroff A; Trial of Indomethacin Prophylaxis in Preterms Investigators. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. *J Pediatr*. 2007;150(3):229–234, 234.e1
46. Wickremasinghe AC, Rogers EE, Piecuch RE, et al. Neurodevelopmental outcomes following two different treatment approaches (early ligation and selective ligation) for patent ductus arteriosus. *J Pediatr*. 2012;161(6):1065–1072
47. Fanos V, Benini D, Verlatto G, Errico G, Cuzzolin L. Efficacy and renal tolerability of ibuprofen vs. indomethacin in preterm infants with patent ductus arteriosus. *Fundam Clin Pharmacol*. 2005;19(2):187–193
48. Shorter NA, Liu JY, Mooney DP, Harmon BJ. Indomethacin-associated bowel perforations: a study of possible risk factors. *J Pediatr Surg*. 1999;34(3):442–444
49. Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. *Pediatrics*. 2004;114(6):1649–1657
50. Van Bel F, Van de Bor M, Stijnen T, Baan J, Ruys JH. Cerebral blood flow velocity changes in preterm infants after a single dose of indomethacin: duration of its effect. *Pediatrics*. 1989;84(5):802–807
51. Pietz J, Achanti B, Lilien L, Stepka EC, Mehta SK. Prevention of necrotizing enterocolitis in preterm infants: a 20-year experience. *Pediatrics*. 2007;119(1). Available at: www.pediatrics.org/cgi/content/full/119/1/e164
52. Vanhaesebrouck S, Zonnenberg I, Vandervoort P, Bruneel E, Van Hoestenbergh MR, Theyskens C. Conservative treatment for patent ductus arteriosus in the preterm. *Arch Dis Child Fetal Neonatal Ed*. 2007;92(4):F244–F247
53. Jhaveri N, Moon-Grady A, Clyman RI. Early surgical ligation versus a conservative approach for management of patent ductus arteriosus that fails to close after indomethacin treatment. *J Pediatr*. 2010;157(3):381–387, 387.e1
54. Kaempf JW, Wu YX, Kaempf AJ, Kaempf AM, Wang L, Grunkemeier G. What happens when the patent ductus arteriosus is treated less aggressively in very low birth weight infants? *J Perinatol*. 2012;32(5):344–348
55. Benitz WE. Learning to live with patency of the ductus arteriosus in preterm infants. *J Perinatol*. 2011;31(suppl 1):S42–S48
56. Halliday HL, Hirata T, Brady JP. Indomethacin therapy for large patent ductus arteriosus in the very low birth weight infant: results and complications. *Pediatrics*. 1979;64(2):154–159
57. Smith IJ, Goss I, Congdon PJ. Intravenous indomethacin for patent ductus arteriosus. *Arch Dis Child*. 1984;59(6):537–541
58. Kresch MJ, Moya FR, Ascuitto RJ, Ross-Ascuitto NT, Heusser F. Late closure of the ductus arteriosus using indomethacin in the preterm infant. *Clin Pediatr (Phila)*. 1988;27(3):140–143
59. McCarthy JS, Zies LG, Gelband H. Age-dependent closure of the patent ductus arteriosus by indomethacin. *Pediatrics*. 1978;62(5):706–712
60. Oxford Centre for Evidence-based Medicine—Levels of Evidence. 2009. Available at: <http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/>. Accessed June 25, 2015

Patent Ductus Arteriosus in Preterm Infants

William E. Benitz and COMMITTEE ON FETUS AND NEWBORN

Pediatrics 2016;137;

DOI: 10.1542/peds.2015-3730 originally published online December 15, 2015;

Updated Information & Services

including high resolution figures, can be found at:
<http://pediatrics.aappublications.org/content/137/1/e20153730>

References

This article cites 57 articles, 19 of which you can access for free at:
<http://pediatrics.aappublications.org/content/137/1/e20153730.full#ref-list-1>

Subspecialty Collections

This article, along with others on similar topics, appears in the following collection(s):

Current Policy

http://classic.pediatrics.aappublications.org/cgi/collection/current_policy

Committee on Fetus & Newborn

http://classic.pediatrics.aappublications.org/cgi/collection/committee_on_fetus_newborn

Fetus/Newborn Infant

http://classic.pediatrics.aappublications.org/cgi/collection/fetus_newborn_infant_sub

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:

<https://shop.aap.org/licensing-permissions/>

Reprints

Information about ordering reprints can be found online:
<http://classic.pediatrics.aappublications.org/content/reprints>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since . Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2016 by the American Academy of Pediatrics. All rights reserved. Print ISSN:

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Patent Ductus Arteriosus in Preterm Infants

William E. Benitz and COMMITTEE ON FETUS AND NEWBORN

Pediatrics 2016;137;

DOI: 10.1542/peds.2015-3730 originally published online December 15, 2015;

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://pediatrics.aappublications.org/content/137/1/e20153730>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since . Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2016 by the American Academy of Pediatrics. All rights reserved. Print ISSN:

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

